The Use of Evicel to Reduce Blood Loss in Total Knee Replacement Surgery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10021
- Hospital for Special Surgery
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of degenerative joint disease of the knee in patients medically suitable to undergo unilateral total knee arthroplasty
Exclusion Criteria:
- Known allergies to human blood products.
- History of bleeding disorders.
- Patients with previous arthrotomy, however, with exception of medial or lateral menisectomy.
- Patients taking Lovenox, Plavix, Aggrenox or erythropoetin. (coumadin is acceptable)
- Additionally, any patient with an intra-operative complication (i.e bone fracture, vascular injury) or post-operative complication that would affect bleeding tendency will be excluded although data will be recorded for later analysis. Also, any patient who has a complication with the suction drain (eg inadvertently being pulled out, suction failing) will have the remaining data points recorded and drain measurements will be excluded from analysis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: Evicel
Evicel is a fibrin sealant used for hemostasis when control of bleeding by ligature or other conventional procedures is ineffective or impractical.
It has been shown to stop bleeding in 2 minutes or less.
Evicel is a combination of a biologic activated component containing human fibrinogen and topical thrombin that functions on wet, actively bleeding tissue.
It is a bioresorbable and biocompatible agent.
|
Used for hemostasis to control bleeding.
It has been shown to stop bleeding in 2 minutes or less.
It is a combination of a biologic activated component containing human fibrinogen and topical thrombin functioning on wet, actively bleeding tissue.
|
|
NO_INTERVENTION: no evicel
Patients will receive standard treatment for bleeding as practiced at the Hospital for Special Surgery.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Hemoglobin on Day 0 Compared to Preoperatively
Time Frame: preoperatively and on the day of surgery
|
preoperatively and on the day of surgery
|
|
|
Change in Hematocrit on Day 0 Compared to Preoperatively
Time Frame: preoperatively and day of surgery
|
preoperatively and day of surgery
|
|
|
Change in Hemoglobin On Day 1 Compared to Preoperatively
Time Frame: preoperatively and one day after surgery
|
preoperatively and one day after surgery
|
|
|
Change in Hematocrit on Day 1 Compared to Preoperatively
Time Frame: preoperatively and one day after surgery
|
preoperatively and one day after surgery
|
|
|
Change in Hemoglobin on Day 2 Compared to Preoperatively
Time Frame: preoperatively and two days after surgery
|
preoperatively and two days after surgery
|
|
|
Change in Hematocrit on Day 2 Compared to Preoperatively
Time Frame: preoperatively and two days after surgery
|
preoperatively and two days after surgery
|
|
|
Drain Output
Time Frame: 24 hours post-operatively
|
A measurement of the amount of blood drained from the knee.
|
24 hours post-operatively
|
|
Number of Autologous Transfusion Units Over the Course of the Hospital Stay
Time Frame: perioperatively
|
Units of autologous transfusion for each patient over the course of the hospital stay (an average of 3 days) were recorded.
|
perioperatively
|
|
Units of Homologous Transfusion Over the Course of the Hospital Stay
Time Frame: three days postoperatively
|
Units of homologous transfusion for each patient over the course of the hospital stay (an average of 3 days) were recorded.
|
three days postoperatively
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in International Normalized Ratio (INR) Level on Day 2 Compared to Preoperatively
Time Frame: preoperatively and two days after surgery
|
The INR, a measure of the clotting tendency of blood, is a ratio of a patient's prothrombin time (the time a blood plasma takes to clot after the addition of tissue factor) to a normal prothrombin time.
|
preoperatively and two days after surgery
|
|
Range of Motion on Day 3
Time Frame: 3 days postoperatively
|
A measurement of the degrees of motion of the operated knee three days after surgery.
|
3 days postoperatively
|
|
Visual Analog Pain Scale on Day 3
Time Frame: 3 days postoperatively
|
The visual analog pain scale is a patient-reported measure of pain on a 10-point scale with 0 being no pain and 10 being worst possible pain.
Drawings of faces indicate the level of pain associated with different points on the scale.
|
3 days postoperatively
|
|
Range of Motion at 6 Weeks
Time Frame: 6 weeks postoperatively
|
A measurement of the degrees of motion of the operated knee six weeks after surgery.
|
6 weeks postoperatively
|
|
Visual Analog Pain Scale (at Rest) at 6 Weeks
Time Frame: 6 weeks postoperatively
|
The visual analog pain scale is a patient-reported measure of pain on a 10-point scale with 0 being no pain and 10 being worst possible pain.
Drawings of faces indicate the level of pain associated with different points on the scale.
For the measure of pain at rest, the patient indicates their level of pain while seated or lying down, not moving.
|
6 weeks postoperatively
|
|
Visual Analog Pain Scale (During Activity) at 6 Weeks
Time Frame: 6 weeks postoperatively
|
The visual analog pain scale is a patient-reported measure of pain on a 10-point scale with 0 being no pain and 10 being worst possible pain.
Drawings of faces indicate the level of pain associated with different points on the scale.
For the measure of pain during, the patient indicates their level of pain while doing activities of daily living such as walking and moving from sitting to standing.
|
6 weeks postoperatively
|
|
Visual Analog Pain Scale (During Therapy) at 6 Weeks
Time Frame: 6 weeks postoperatively
|
The visual analog pain scale is a patient-reported measure of pain on a 10-point scale with 0 being no pain and 10 being worst possible pain.
Drawings of faces indicate the level of pain associated with different points on the scale.
For the measure of pain during, the patient indicates their level of pain during physical therapy.
|
6 weeks postoperatively
|
|
Visual Analog Pain Scale (At Night) At 6 Weeks
Time Frame: 6 weeks postoperatively
|
The visual analog pain scale is a patient-reported measure of pain on a 10-point scale with 0 being no pain and 10 being worst possible pain.
Drawings of faces indicate the level of pain associated with different points on the scale.
For the measure of pain at night, the patient indicates their level of pain during or before sleep.
|
6 weeks postoperatively
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Mark P Figgie, M.D, Hospital for Special Surgery, New York
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 29054
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.